Keyphrases
Percutaneous Coronary Intervention
76%
Flow-mediated Vasodilation
38%
Adipose-derived Stem Cells
38%
Tissue Engineering
38%
Stent
38%
Orsiro Stent
38%
Anti-CD34 Antibody
38%
Sirolimus
38%
Occlusion Therapy
38%
COMBO Stent
38%
Clinical Comparison
38%
Dual Therapy
38%
Randomized Clinical
38%
In-stent Restenosis
38%
Chronic Coronary Syndrome
38%
Patient Management
38%
Chronic Total Occlusion
28%
Cell Growth
25%
Replacer
25%
Cell Seeding Density
25%
Target Lesion Revascularization
23%
Stenosis
21%
Coronary Chronic Total Occlusion
19%
Retrograde Technique
19%
Target Lesion Failure
17%
Confidence Interval
17%
Fetal Calf Serum
12%
Gaseous Environment
12%
Precursor Cells
12%
Subcutaneous Adipose Tissue
12%
Hypoxic Culture
12%
Medium Composition
12%
Cardiac Failure
12%
Cell Yield
12%
Differentiation Potential
12%
Human Mesenchymal Stem Cells (hMSCs)
12%
Nucleated Cells
12%
Clinical Trials
12%
Supporting Cells
12%
Eagle
12%
Adverse Cardiac Events
12%
Non-inferiority
10%
Procedural Failure
9%
New York Heart Association
9%
Lesion Complexity
9%
Retrograde Approach
9%
Antegrade Wire Escalation
9%
Cardiovascular Mortality
9%
Randomized Controlled Trial
9%
Invasive Strategy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Rapamycin
76%
CD34 Antibody
76%
Heart Infarction
49%
Omega-3 Fatty Acid
38%
Adiponectin
38%
Heart Failure
38%
Randomized Clinical Trial
38%
Chronic Total Occlusion
38%
In-Stent Restenosis
38%
Heart Muscle Ischemia
38%
Pharmacotherapy
27%
Stenosis
25%
Ischemic Heart Disease
20%
Icosapentaenoic Acid
15%
Major Adverse Cardiac Event
12%
Docosahexaenoic Acid
11%
All Cause Mortality
10%
Heart Death
10%
Randomized Controlled Trial
9%
Apolipoprotein B
6%
Antiplatelet
5%
Sulfanilamide
5%
Cardiovascular Risk
5%
Hypocholesterolemic Agent
5%
Anticoagulant Agent
5%
Medicine and Dentistry
Percutaneous Coronary Intervention
100%
Heart Muscle Ischemia
46%
Rapamycin
38%
Coronary Occlusion
38%
Chronic Total Occlusion
38%
Randomized Clinical Trial
38%
In-Stent Restenosis
38%
Target Lesion
27%
Stenosis
21%
Target Lesion Revascularization
20%
Fetal Bovine Serum
19%
Cardiovascular System
17%
Major Adverse Cardiac Event
12%
Quality of Life
9%
Diagnostic Testing
9%
Health Care Cost
9%
Randomized Controlled Trial
9%
Hazard Ratio
8%
Heart Failure
7%
Adverse Event
7%
Cohort Analysis
7%
Angina Pectoris
7%
Patient Characteristics
7%
New York Heart Association Class
7%
Symptom
7%
